These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 28476415)

  • 1. [What are the socio-economic consequences of acute COPD exacerbations?].
    Bourdin A; Molinari N
    Rev Mal Respir; 2017 Apr; 34(4):338-342. PubMed ID: 28476415
    [No Abstract]   [Full Text] [Related]  

  • 2. Hospital admissions related to acute exacerbations of chronic obstructive pulmonary disease in France, 1998-2007.
    Fuhrman C; Roche N; Vergnenègre A; Zureik M; Chouaid C; Delmas MC
    Respir Med; 2011 Apr; 105(4):595-601. PubMed ID: 21130636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Estimation of direct medical costs of chronic obstructive pulmonary disease over 12 months].
    Stâmbu I; Stoicescu IP
    Pneumologia; 2013; 62(2):86-92. PubMed ID: 23894789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Management and costs of chronic pulmonary obstructive disease in France in 2011].
    Laurendeau C; Chouaid C; Roche N; Terrioux P; Gourmelen J; Detournay B
    Rev Mal Respir; 2015 Sep; 32(7):682-91. PubMed ID: 25613440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs of COPD exacerbations in the emergency department and inpatient setting.
    Dalal AA; Shah M; D'Souza AO; Rane P
    Respir Med; 2011 Mar; 105(3):454-60. PubMed ID: 20869226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Costs of exacerbations of chronic obstructive pulmonary disease in primary and secondary care in 2007--results of multicenter Polish study].
    Jahnz-Rózyk K; Targowski T; From S
    Pol Merkur Lekarski; 2009 Mar; 26(153):208-14. PubMed ID: 19388534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Costs of chronic obstructive pulmonary disease in patients treated in ambulatory care in Poland].
    Jahnz-Różyk K; Targowski T; From S; Faluta T; Borowiec L
    Pneumonol Alergol Pol; 2011; 79(5):337-42. PubMed ID: 21861257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [COPD--chronic obstructive pulmonary disease and its implications for the human organism].
    Groneberg DA; Pleimes D; Golpon H; Welte T
    Versicherungsmedizin; 2006 Sep; 58(3):116-9. PubMed ID: 17002174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review.
    Toy EL; Gallagher KF; Stanley EL; Swensen AR; Duh MS
    COPD; 2010 Jun; 7(3):214-28. PubMed ID: 20486821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asthma and Chronic Obstructive Pulmonary Disease Overlap Syndrome: Doubled Costs Compared with Patients with Asthma Alone.
    Gerhardsson de Verdier M; Andersson M; Kern DM; Zhou S; Tunceli O
    Value Health; 2015 Sep; 18(6):759-66. PubMed ID: 26409602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement in COPD management by access to asthma/COPD clinics in primary care: data from the observational PATHOS study.
    Lisspers K; Johansson G; Jansson C; Larsson K; Stratelis G; Hedegaard M; Ställberg B
    Respir Med; 2014 Sep; 108(9):1345-54. PubMed ID: 25002194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [What are the definitions of acute COPD exacerbations and COPD decompensations?].
    Chabot F
    Rev Mal Respir; 2017 Apr; 34(4):327-330. PubMed ID: 28476416
    [No Abstract]   [Full Text] [Related]  

  • 13. [Retrospective analysis of direct costs of hospital treatment of chronic obstructive pulmonary disease exacerbations].
    Jahnz-Rózyk K; Targowski T; From S; Płusa T
    Pol Merkur Lekarski; 2004 May; 16 Suppl 1():91-4. PubMed ID: 15524028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COPD costs to approach $50B per year in 2020.
    Manag Care; 2014 Sep; 23(9):57. PubMed ID: 25282870
    [No Abstract]   [Full Text] [Related]  

  • 15. The cost of COPD exacerbations: a university hospital--based study in Greece.
    Geitona M; Hatzikou M; Steiropoulos P; Alexopoulos EC; Bouros D
    Respir Med; 2011 Mar; 105(3):402-9. PubMed ID: 20970310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of home hospitalization on healthcare costs of exacerbations in COPD patients.
    Puig-Junoy J; Casas A; Font-Planells J; Escarrabill J; Hernández C; Alonso J; Farrero E; Vilagut G; Roca J
    Eur J Health Econ; 2007 Dec; 8(4):325-32. PubMed ID: 17221178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors after hospitalization for COPD exacerbation.
    Fuhrman C; Moutengou E; Roche N; Delmas MC
    Rev Mal Respir; 2017 Jan; 34(1):1-18. PubMed ID: 27368501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD).
    Friedman M; Menjoge SS; Anton SF; Kesten S
    Pharmacoeconomics; 2004; 22(11):741-9. PubMed ID: 15250751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The direct and indirect costs of managing chronic obstructive pulmonary disease in Greece.
    Souliotis K; Kousoulakou H; Hillas G; Tzanakis N; Toumbis M; Vassilakopoulos T
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1395-1400. PubMed ID: 28546747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Is it possible to shorten the antibiotic therapy in patients hospitalized for acute COPD exacerbation?].
    Vandenbos F; Caisso C; Harb E; Vidal R; Nicolle I; Risso K; Roger PM;
    Rev Mal Respir; 2017 Mar; 34(3):275-277. PubMed ID: 28189433
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.